HMNC Brain Health is a disruptive clinical stage biopharma company pioneering Precision Psychiatry, powered by its AI Platform, and focusing on Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD).

HMNC Brain Health uses its AI Platform, combining Psychiatry, Genomics, and Analytics, to develop innovative therapies for mental health disorders.

HMNC Brain Health’s Precision Psychiatry approach, based on more than 30 years of research, addresses a high unmet medical need arising from today’s non-specific, often insufficient, and side-effects laden treatment of patients.

HMNC Brain Health is paving the way for the targeted use of antidepressants through co-developing novel compounds with matching IP protected companion diagnostics, powered by its AI platform.